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Abstract We propose a structural relationship between the value of preventing a
statistical cancer fatality and the value of statistical life (VSL) for risks of an instanta-
neous road accident fatality. This relationship incorporates a context effect reflecting
both the illness or ‘morbidity’ associated with cancer fatality and the ‘dread’ or horror
associated with the prospect of eventual death from cancer, as well as a latency effect
that captures the discounting likely to arise because the onset of the symptoms of cancer
typically occurs after some delay. We use a Risk-Risk trade-off study to validate this
model by directly estimating the influence of context and latency effects upon the
relative size of the VSL for cancer and for road accidents, confirming that both effects
are significant and estimating their size using regression analysis. We show that
morbidity accounts for the majority of the context premium. We use the elicited
coefficients to reconstruct VSL estimates for a range of cancers characterised by their
latency and morbidity periods.
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1 Introduction
The Value of Statistical Life 1 (VSL) reflects the monetary value to the affected
population of a small reduction in the risk of premature death (Jones-Lee 1989). In
the UK, it is conventionally defined as the aggregate willingness to pay by a large,
representative sample of individuals for small reductions in the risk of death which,
taken across the group concerned, will reduce the expected number of fatalities during a
forthcoming period by one and will hence save one Bstatistical life^. As such, the VSL
will clearly be determined by the marginal rate of substitution (MRS) of wealth for risk
of death for individuals within the affected group, and for a group enjoying equal
marginal risk reductions, it will be equal to the arithmetic mean MRS for the group
concerned—see, for example, Jones-Lee (1989) and Viscusi (1998). By contrast, in the
USA, the term is typically applied directly to the MRS. Both definitions clearly share
the same conceptual foundations. In the study reported in this paper, we analyse the
data at the individual level which is akin to the US approach, although for UK policy
extrapolation we aggregate the data to conform with the UK definition and application
of the VSL.
In the UK, the (aggregated) VSL was initially implemented in the transport sector
(Jones-Lee et al. 1985) and elicited in this context. However, increasingly there has
been a policy-driven trend to extend its use to other sectors, both in the UK and
elsewhere, as has been noted by the Organisation for Economic Co-operation and
Development (OECD 2012). Whilst intuitively we might expect contextual factors
including the mode of death to affect the perceived value of risk reductions, govern-
ments generally apply the same VSL across contexts. The exception is when the change
in risk applies to cancer fatalities, as exemplified by the UK Health and Safety
Executive (HSE)’s 2001 current recommendation for a cancer VSL.2
‘Where the benefit is the prevention of death, the current convention used by HSE,
when conducting a CBA is to adopt a benchmark value of about £1,000,000 (2001
prices) for the value of preventing a fatality (VPF). This is the VPF adopted by the
Department of Transport, Local Government and the Regions for the appraisal of
road safety measures. It may well be the case that individuals’ willingness to pay
for risk reduction—measured in aggregate by the VPF—will vary, depending on
the particular hazardous situation. Thus, the particular hazard context will need to
be borne in mind when a VPF figure is adopted. Currently, HSE takes the view
that it is only in the case where death is caused by cancer that people are prepared
to pay a premium for the benefit of preventing a fatality and has accordingly
adopted a VPF twice that of the roads benchmark figure. Research is planned to
assess the validity of this approach.’ (HSE 2001)
Applying a cancer premium to the VSL is principally intended to reflect the fact that
death from cancer is typically preceded by a protracted period of ill-health and dread
caused by the prospect of imminent fatality. In addition, evidence from the first stated
1 Also termed the Value of Preventing a Statistical Fatality (VPF) in the UK.
2 The Directorate-Generale of the EU takes a similar position, recommending a cancer premium of 1.5
(see European Commission 2001).
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preference-based VSL study conducted in the UK indicated that as far asmembers of the
public were concerned, willingness to pay (WTP) for a given reduction in the number of
deaths from cancer was almost double the corresponding amount for reducing the
number of road accident deaths by the same figure—see Jones-Lee et al. (1985). This
position is supported by economic theoretic and psychological evidence which suggests
that willingness to pay for risk reductions may naturally be expected to vary across
causes, for example because of differing baseline exposure risks (Pratt and Zeckhauser
1996; Covey 2001) or personal risk perception (Slovic 1987; McDaniels et al. 1992).
When well-informed and carefully considered survey responses generate a VSL that
incorporates a premium for certain types of fatality, then a strong case can be made that
the VSL figure used in policy making should reflect this premium.
2 Context, latency and cancer risks
Nevertheless, two important reservations can be made with respect to the upward
adjustment of the VSL for cancer (hereafter VSLCANCER). The first relates to the fact
that death from cancer will not take place immediately even if exposure to this risk is in
the current period. This is due to the latency period in the development of most cancers.
Latency is defined as the delay between an individual’s exposure to the conditions that
are the basic cause of cancer and the onset of symptoms, with death occurring after a
period of illness referred to as the Bmorbidity period^. Recognising latency is important
in the policy process, because typically a policy is implemented in the current period to
reduce the risk of developing and dying from cancer in the future. For example workplace
policies often reduce the exposure of workers to radiation or other carcinogens, and air
pollution reductionmeasures implemented now reduce the risk of developing lung cancer
in the future. Economic theory (and empirical evidence) suggests that people discount
future events relative to present events (Samuelson 1937; Frederick et al. 2002), in part
due to the inherent uncertainty about reaching that future point, but also due to an intrinsic
preference for good things to happen now, and bad things later. Epidemiological evidence
indicates that this latency delay will typically be in the region of 5–25 years.3 When
comparing the VSL for cancer with the figure applicable to road fatalities it therefore
seems likely that to some extent latency delays will mitigate the context effects referred to
earlier. Valuations from studies that do not incorporate a latency period into the cancer
description will be unable to capture this (potentially) offsetting effect and so using these
valuations to inform policies that affect latent cancer risks could result in overvaluing the
avoidance of future cancer fatality risks relative to the avoidance of fatality risks in the
current period. The extent to which various empirical studies control for latency has been
explored in Viscusi (2013) and the need for more comprehensive treatment of future risks
has recently been considered by Cameron and DeShazo (2013).
The second reservation stems from the lack of conclusive evidence in the literature
either for or against the application of a cancer premium.4 A number of studies use
information on revealed preferences, typically using data on house prices and environ-
mental cancer risks—for example, Gayer et al. (2000); Gayer et al. (2002), and Davis
3 These figures refer to occupational cancers for which official data are available (Rushton et al. 2010).
4 This review is by necessity brief. For a more comprehensive discussion see Viscusi (2013).
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(2004). On the basis of these three studies, there is no evidence to suggest that latent
cancers are valued at a premium compared to instant road accident fatalities.
Turning to the stated preference literature, evidence in support of a cancer premium
can be found in an early study by Van Houtven et al. (2008) as well as in Alberini and
Scasny (2010) and (2011). These studies find, respectively, premia of 3:1 (for a latency
of 5 years, dropping to 1.5 when the latency period increases to 25 years in the US), 2:1
(Italy) and 2.5:1 (Czech Republic). Viscusi et al. (2014), holding latency constant at
10 years, find evidence of a statistically significant cancer premium of 21%.
In contrast, a number of studies find no evidence of a significant cancer premium.
An early example by Magat et al. (1996) finds a cancer to roads VSL relativity of 1:1.
They include detailed morbidity descriptions but do not specify any latency. Hammitt
and Liu (2004) directly test the effects of disease type and latency and find that while
latency (20 years) has a significant effect on willingness to pay for risk reductions, there
is no statistically significant effect of cancer.5 Hammitt and Haninger (2010) find no
significant difference between the values of risk reductions for cancer compared to any
other cause, including road accidents, in the US. Adamowicz et al. (2011) find that
cancer risk reductions are in fact valued less than microbial disease risk reductions.
Finally, it should not be surprising, given the above discussion, that between the
group of studies that support a cancer premium and the group that finds evidence
against one, there is a range of studies that find mixed or inconclusive results on the
matter (Tsuge et al. 2005, Japan; Cameron et al. 2009, US).
A summary of the stated preference studies, including information about the latency
and morbidity periods involved, is provided in Table 1. Notice that while some studies
reported terminal and curable cancers, where we provide a value for the premium it is
for fatal cancer compared to instant road accident fatality. Clearly, the studies differ in
methodology and country, but also in the information respondents were given, partic-
ularly regarding morbidity and latency.
Some of the studies examined do not specify for respondents what kind of cancer is to
be considered, which means that respondents are left to imagine the symptoms, which
then lie outside of the researchers’ control. Examples are Alberini and Scasny (2010) and
Alberini and Scasny (2011) who give Bbasic information^ and Tsuge et al. (2005). A full
meta-analysis of stated preference studies (OECD 2012) did not find evidence to suggest
a cancer premium, instead recognising that the morbidity preceding fatality generates a
higher value for cancer risk reductions, but recommending that morbidity costs prior to
death should be added separately as opposed to being incorporated in a cancer premium.
More recent research by Cameron and DeShazo (2013) recognises the heterogeneity
of fatality risk scenarios and explicitly addresses latency and morbidity in a choice
experiment where the scenarios vary along these dimensions. Their results suggest that
both latency and morbidity are important in explaining the VSL, with longer morbidity
prior to fatality engendering higher WTP to avoid the risk than shorter morbidity, and
that for older members of the sample, VSL for latent fatality is lower than for more
immediate fatality risks. They do not, however, report the case of cancer explicitly,
instead using cancer scenarios for describing the profiles but reporting aggregated
results across illnesses.
5 Hammitt and Liu (2004) find a premium of around one-third, but it is not statistically significant at
conventional levels.
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Based on the review of the literature, we propose that the lack of consensus in the
cancer VSL literature may reflect the different information that is presented to respon-
dents about the latency periods associated with cancer. While techniques are well
developed for eliciting the overall relativity for a latent cancer fatality compared to a
road accident fatality, with just a handful of exceptions, limited progress has been made
in the separate analysis of the effects of context and of latency. We feel that this is a
serious shortcoming of the literature, as well as an explanation for the discrepancy in
elicited cancer premium values. Essentially, if delayed fatality risks are indeed
discounted by respondents in valuation studies, then each point estimate of the
cancer VSL is not generalizable away from the specific context and delay for
which the relativity was elicited. However, if the effective discount rate can be
disentangled from the (time invariant) context effects, then it would be possible to
apply the valuation to cancer scenarios with different latency periods. The ‘dread’
and latency effects are well documented as discussed, but the literature lacks a
framework for their specific and simultaneous analysis. To address this, we propose
the following structural relationship:
CT
Rt
¼ 1þ xð Þ
1þ rð Þ T−tð Þ
ð1Þ
In which CT is the VSLCANCER when the cancer fatality would occur at time T, Rt is
the VSL for risks of road accident fatalities which would occur at time t (t≤T), (1 + x)
is a scalar which captures the effects of the context of cancer, including dread and
morbidity effects; and r is the discount rate which is assumed to be exponential for
tractability.6 We apply discounting to all periods until fatality would occur, and as such
both the latency and morbidity periods contribute to the discount factor. In this
framework, we capture the major qualitative differences between cancer fatality and
road accident fatality risk valuations. We can use the framework to elicit estimates of
the context premium (1 + x) and the discount rate (r).
In what follows, we present a survey that supports the proposed CTRt relationship by
confirming the directional effects of context and latency in a controlled survey design.
We verify that the context of cancer increases the relative size of the VSL, and that
longer latency periods reduce it, ceteris paribus. We estimate the size of the context and
latency effects using regression analysis. The data are then used to investigate the
overall relativities between the VSL for cancer with different latency and morbidity
characteristics, and that for instantaneous road accident fatalities.
3 Methods
3.1 Risk-Risk trade-offs
The Risk-Risk trade-off method, developed by Viscusi et al. (1991), and extended in
Magat et al. (1996) and Van Houtven et al. (2008), allows respondents to compare risks
6 The relationship can be adapted for hyperbolic and other discounting hypotheses simply by adjusting the
denominator.
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of fatality in one cause with risks of fatality in another, thereby avoiding the need for
complex money-risk trades that are necessary for standard contingent valuation. It also
reduces the likelihood of scope insensitivity problems as documented in Jones-Lee
et al. (1985) or Beattie et al. (1998). The method provides a measure of the
strength of preference for avoiding specified risks, and has been shown by Van
Houtven et al. (2008) to be viable in investigating preferences over cancer
fatalities.
Following Viscusi et al. (1991); Magat et al. (1996), and Van Houtven et al. (2008)
this model incorporates three possibilities, death in a road accident (D), death by cancer
(C) and full health (H) resulting from avoidance of death in a road accident or by
cancer. These have corresponding lifetime utilities that depend on both the cause of
death and on wealth, w, represented by U(D,w), U(C,w) and U(H,w); and respective
probabilities πD, πC and (1 -πD -πC).
Therefore expected lifetime utility is given by
E Uð Þ ¼ πDU D;wð Þ þ πCU C;wð Þ þ 1−πD−πCð ÞU H ;wð Þ ð2Þ
Now consider a choice between two options, A and B, where the probabilities of
road accident and cancer fatality differ. These are denoted πAD, π
B
D, π
A
C, and π
B
C .
For an expected utility maximiser, indifference between options A and B implies:
πADU D;wð Þ þ πAC U C;wð Þ þ 1−πAD−πAC
 
U H ;wð Þ
¼ πBDU D;wð Þ þ πBC U C;wð Þ þ 1−πBD−πBC
 
U H ;wð Þ ð3Þ
To recast the analysis in terms of the VSL, recognise that the standard VSL is
defined as the marginal rate of substitution between wealth and risk of an instant road
accident fatality. Similarly, the VSLCANCER is the marginal rate of substitution between
wealth and risk of cancer fatality. Setting U(D) equal to zero (with no loss of generality)
and differentiating Eq. (2) with respect to πD, πC, and wealth, Van Houtven et al. (2008)
show that the relativity between VSLCANCER and the standard VSL is
VSLCANCER
VSL
¼ 1− U C;wð Þ
U H ;wð Þ ð4Þ
So that with U C;wð Þ < 0 < U H ;wð Þ then VSLCANCERVSL > 1, while with 0 < U C;wð Þ
< U H ;wð Þ then VSLCANCERVSL < 1. That is, the framework does not constrain U(C,w) to be
greater than or smaller than U(D,w).
Of course, it is not possible to directly observe utilities from Risk-Risk survey data.
Instead, we observe the relative sizes of risk changes that make respondents indifferent
between options A and B. From Eq. (3), with U(D,w) = 0, then
U C;wð Þ ¼ 1− π
B
D−πAD
πAC−πBC
  
U H ;wð Þ ð5Þ
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Rearranging, and in combination with Eq. (4),
VSLCANCER
VSL
¼ 1− U C;wð Þ
U H ;wð Þ ¼
πBD−πAD
πAC−πBC
ð6Þ
By observing the relative sizes of πD and πC that make respondents indifferent
between options A and B, one can therefore determine the relative size of the value of
statistical life for one cause compared to another. This result, previously demonstrated
in Van Houtven et al. (2008), makes intuitive sense in that if the change in cancer risk
between options A and B is precisely offset for the respondent by the change in road
accident risk, then the ratio of the respondent’s MRS of wealth for risk (i.e. the ratio of
his/her VSLs) must be equal to the inverse of the ratio of the risk changes. More
specifically, if a person has a VSLCANCER:VSLROADS ratio (or Brelativity^) of two, it
implies they would be indifferent between an increase (decrease) in their risk of road
accidents that is twice as large as the increase (decrease) in their risk of cancer fatality.
Further, the relative size of the VSL for cancer and road accidents, and the relative size
of the risk differences that render the respondent indifferent, reflect the proportional
utility loss in the case of cancer U H ;wð ÞU C;wð ÞU H ;wð Þ
 	
.
3.2 Survey
We administered a Risk-Risk trade-off survey to capture the relative VSL for roads and
cancer with different latency periods. The survey was administered in a small group
setting, as part of a wider interview protocol with three stages. 7 All answers were
elicited on an individual basis.
The first stage comprised a combination of learning exercises designed to familiarise
respondents with the type of questions and elicitation procedures used in Risk-Risk
trade-off studies. There were also some structured questions and open-ended discus-
sions to check for comprehension of key concepts such as risk and timing of death. We
emphasised the cost to the individual of accepting a bigger risk increase in their less
feared cause by reminding them about the resulting increase in their total risk of death.
Respondents were reminded that this cost could be avoided by switching to the smaller
increase in the risk of their more feared cause.8 The later phase introduced the two risk
contexts to be considered in the main survey—death in a road accident and death by
cancer. We also introduced the pictorial representations that would be used to describe
the scenarios, so-called BProfiles^ (Fig. 1) as well as the symptoms associated with a
typical cancer case. The symptoms were described in as much detail as possible,
7 Extracts are provided in the appendix, and the full interview protocol and questionnaire are available on
request.
8 In piloting, the Risk-Risk trade-off questions used risk decreases, but this proved too cognitively complex for
most respondents and generated implausibly large relativities. We changed to the domain of risk increases,
using the scenario of spending reductions in the government’s safety budget. Under Expected Utility theory,
marginal increases and decreases in risk can be assumed to have equal magnitude because of the assumption
that linearity holds at the margin. The proposed analysis is unaffected by the choice of risk increases or risk
reductions. Despite using risk increases the elicited relativities were still very large. As a result we developed a
pie-diagram that illustrated the direct Bcost^ to the respondent of taking the bigger risk increase; specifically,
the larger increase in total risk of death.
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without losing the generality of the scenario. An extract from the experimenter’s script
describing the cancer symptoms, along with other aspects of the cancer scenarios, is
provided in the appendix. We specified that the cancers were not behaviour-related
(for example, not smoking-related), instead being due to exposure to environmental
or workplace causes.
The cancers described had three key timing features: time of exposure, time of
symptom onset, and time of death. These then determined the latency and morbidity
periods.9 Notice that we never explicitly referred to Blatency^ or Bmorbidity^ in the
experiment, instead referring to Bthe time until you would become ill^, Bthe time spent
ill^ and Bthe time of your death^, to simplify the explanation (see the appendix for some
example text). In every case, the individual would be exposed to the carcinogen during
the coming year; however, the latency and morbidity periods varied across scenarios.
So, for example, cancer fatality in 10 years refers to exposure during the coming year,
onset of symptoms after 9 years, and death 1 year after that, 10 years from now.
An important distinction is the time of exposure (in our questions, this was always
during the coming year, with any associated monetary costs or savings happening now)
and the time that the cancer would physically manifest itself (encompassing illness and
death).
The second stage of the session comprised the ten Risk-Risk trade-off questions.10
These are summarised in Table 2, along with a brief description of the purpose of each
question. In every case, both baselines were presented as 1000 in 60 million. The
denominator of 60 million was chosen because it is the size of the UK population, and
respondents were informed of this to help them to put the size of the risks into
meaningful context. We chose 1000 as the numerator because the average road accident
Fig. 1 Profiles used to describe the cancer and road accident fatality scenarios
9 We vary duration of illness as opposed to severity because duration is an objectively increasing measure of
illness. The analysis could usefully be extended to consider severity of symptoms in future.
10 All respondents answered all ten questions and as such there exists a danger of Banchoring^ or Blearning^
leading to non-independent responses, as well as fatigue. To ensure that the relativities to be used in the
calculation of the parameter values r and (1 + x) were free from these particular biases, we chose to ask the
‘overall’ questions (Q1-Q3) first for every respondent. We decided against random ordering of the remaining
questions, instead keeping a logical ordering of question sets, to avoid confusing respondents by frequently
switching contexts, duration etc. We did, however, reverse the order of questions within sections to minimize
any anchoring or learning effects between questions where direct comparisons would be made.
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risk in the UK can be rounded up to 1000 in 60 million.11 In addition, the attributes of
the cancers presented (typical latency and typical morbidity period) mean that we can
construct groups of cancers with those properties, and cancers can be chosen such that
the group’s overall baseline is close to 1000 in 60 million.12
Q1–Q3 most closely match those typically asked in the literature. The comparison
was between road accidents during the coming year (in Q1) or during the year after
next (in Q2–3) and cancers with 9 or 24 years of latency, one year of morbidity and
then fatality after a total of 10 or 25 years. These latencies were chosen to provide
information for a credible range of latency periods for a variety of cancers. Throughout,
we refer to this latent cancer to current roads relativity as the Boverall premium^. The
relativity was elicited for the risks of cancer fatality in 10 years relative to both road
fatality risks in the current year and also for road fatality risks the year after next, in case
a strong ‘present bias’ was prevalent in responses to Q1. If preferences were present-
biased, then the weight on avoiding a risk increase in the coming year would be large
relative to that for future years, generating a potential for respondents to overstate the
acceptable future risk to avoid an increase in current period risk, however small. For
notation, these questions will be referred to as C10R1, C10R2 and C25R2 where the letter
denotes the cause of death (context) and the number denotes the number of years until
fatality. In the cancer case, this incorporates T-1 years of latency and a fixed 1 year
morbidity period. For road accidents, we described the morbidity period as lasting
Bminutes or hours^. These questions provide information about the level of the overall
cancer premium for a given latency and morbidity.
A multiple-list elicitation format was adopted. The method and materials are similar
to those explained in Chilton et al. (2006)). The method is analogous to a payment card
11 The reason for equalising the baselines is that very early in the piloting stage, it became apparent that
baseline impacts would overwhelm any dread or latency effects of the sort we aimed to elicit.
12 Derived from the HSE Dataset BInput data for cancer registrations^.
Table 2 Risk-Risk questions
Purpose Question Explanation Code
Premium* Q1 Road death in the coming year vs cancer death in 10 years C10: R1
Q2 Road death the year after next vs cancer death in 10 years C10:R2
Q3 Road death the year after next vs cancer death in 25 years C25:R2
Context Q4 Road death the year after next vs cancer death year after next C2:R2
Q5 Road death in 10 years vs cancer death in 10 years C10:R10
Latency Q6 Cancer death year after next vs cancer death in 10 years C2:C10
Q7 Cancer death year after next vs cancer death in 25 years C2:C25
Morbidity Q8 Cancer death in 10 years (6 months’ illness prior to death) vs
Cancer death in 10 years (1 year’s illness prior to death)
C10[12 m]:
C10[6 m]
Q9 Cancer death in 10 years (6 months’ illness prior to death) vs
Cancer death in 10 years (3 years’ illness prior to death)
C10[36 m]:
C10[6 m]
Labelling Q10 Road death in 10 years (1–2 weeks’ illness prior to death) vs
Cancer death in 10 years (1–2 weeks’ illness prior to death)
C10[2w]: R10[2w]
*Premium questions incorporate differences in latency, morbidity and context in an overall comparison
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procedure in the context of a WTP question and shares its associated advantages and
disadvantages. In each question, respondents were asked to choose between increases
in their risk of dying by one of the two causes if the increase in risk was 50 in 60
million in both cases (or to express indifference). Then they were asked to choose
between the two risk increases in each row, and hence to reveal what level of risk
increase would make them Bswitch over^ to the smaller increase in the other risk. This
reveals a narrow range for their indifference point in the table.13 For example, if a
respondent chose to accept the increase in their road accident fatality risk, they received
an answer sheet in which the road accident risk was increased in each row.14 We
analyse the first row in which they would prefer to take the smaller risk increase
(50 in 60 million) in the other, more feared cause of fatality. This switching point
forms the basis for the calculation of marginal rates of substitution described in the next
section. If a respondent reached the bottom of the table and had not yet switched from
their most preferred risk increase, they were asked to indicate the highest risk increase
that they would be prepared to incur before switching. This ensures that data are
available to calculate relativities for respondents with Bextreme^ preferences.15
Subsequent to questions that elicit the overall premium (Q1–3), respondents an-
swered seven further questions designed to verify the structural relationship proposed
in Eq. (1). These questions also allow us to run some individual-level scope tests. Q4–5
estimate the significance of the context premium, since the timing of death is held
constant in each of the questions. Morbidity is again fixed at 12 months for the cancer
and Bminutes or hours^ for the road accident. These questions (and resulting relativ-
ities) have the labels C2R2 and C10R10 following the convention outlined above. Q6–7
(C2C10 and C2C25) capture latency effects by comparing cancer fatalities now and in
the future, holding context and morbidity constant. Q8–9 capture morbidity effects by
varying the period that the individual is ill prior to death, but holding the timing of
death constant. The notation is extended to include the number of months of illness in
square brackets (see Table 2). Q4–9 provide some validity to the context premium
results, as well as generate grounds for future investigation of what might drive the
context premium. Finally, Q10 is designed to rule in or rule out any ‘labelling’ effects
i.e. whether the word Bcancer^ triggers a stronger preference for avoiding this risk, even
when the morbidity period is the same in both cases.
13 We analyse the mid-point of this range as their indifference point.
14 A potential confound arises because respondents may be able to deduce when others expressed indifference
between the initial risk increase because they would not receive a second answer sheet. It is unclear which
direction this might bias respondents (if any), but it may induce respondents to herd towards or away from
stating indifference during the course of the session. We checked the number of ‘indifference’ answers per
question order and found no evidence that the number or proportion of ‘indifference’ responses increased or
decreased as the survey progressed. We note that there were a small minority of indifference responses, and for
Q1–9 they made up just 7.14 % of the total responses. We also checked for a peak at the first row of switching
which could indicate people being reluctant to publicly admit indifference between the two risks. This was not
evident.
15 To check for any obvious biases in our responses due to the use of this elicitation mechanism, we ran some
standard checks. Only one respondent switched multiple times in our survey. Plotting the frequency distribu-
tion provided no strong evidence to suggest that responses were clustered around the middle of the table. Of
the responses from within the body of the table, the modal switch-point was in row 6 of 9. A large proportion
of respondents switched just below the table, indicating values of up to 800 in 60 million. A similar proportion
indicated indifference. This suggests that respondents did not feel constrained by the endpoints of the table.
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The final stage contained questions designed to elicit respondents’ attitudes to
financial risk; time preferences; and health risk preferences, all of which could help
to explain respondents’ R-R trade-offs. Demographic questions concluded the session,
which lasted about one and three quarter hours.
4 Results
One hundred fifty-seven residents of the City of Newcastle Upon Tyne, UK were
interviewed in January 2012. The respondents were aged between 30 and 50 and
broadly representative of the population of the North East of England in that age
cohort, although unemployed people were slightly overrepresented. Table 3 displays
mean values with standard errors in parentheses.
We present the central tendency results in Table 4, using the geometric mean for
each relativity since this central tendency measure is arguably the best suited to the
analysis of ratio data, avoiding the bias associated with the arithmetic mean16 and
displaying more sensitivity than the median. The results are not qualitatively affected
by this choice. The table shows the number of responses removed during data cleaning,
where protests are taken out of the dataset. These are defined as responses stating that
no amount of risk increase would induce them to switch, probabilities greater than 1, or
in one case, a response indicating multiple switchpoints. Unanswered questions are also
included. 64.2% of respondents provided an answer to every question in the survey, and
only 3.1% gave a protest response in all ten questions.
On reviewing the remaining data we found a proportion of high-end outliers in
the initial dataset, and we trimmed the dataset as follows. First, we set a threshold
above which we felt answers were unreasonably high. We chose to exclude
responses of 30 million in 60 million and above (i.e. any response saying BI would
switch if the increase in the risk of my less feared cause rose to 30 million in 60
million^ or more). Remember that the risk of their initially less preferred cause was
only 50 in 60 million, and so a response of 30 million or more suggests that
respondents considered their most feared cause to be 600,000 times as bad as their
less feared cause.17
We trim on an individual question basis as opposed to a respondent basis, by
removing specific responses that fell above the thresholds. Between 0 and 14 responses
were trimmed from each question. 79.6% of respondents did not have any responses
trimmed from the dataset, 5.0% had just 1 response removed, and no one had all ten
responses trimmed, which suggests that a proportion of individuals made errors or
expressed very strong preferences in a subset of questions. This behaviour was most
common in the latency questions (comparing cancer at two different times), perhaps
reflecting lexicographic preferences for delaying the fatality.
After trimming, the remaining per-question sample size ranges are from 117 to 139.
We present the untrimmed and trimmed responses in Table 4. However we focus on the
trimmed dataset for the purpose of commentary.
16 In which the cause of death in the numerator is effectively over-weighted.
17 Some respondents were prepared to accept a risk increase of 50 million in 60 million, indicating a premium
of 1 million to 1.
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4.1 Validating the CTRt relationship
The central tendencies of the relativities provide evidence in support of the CTRt
relationship proposed in Eq. (1). We find a positive effect of context and morbidity,
while latency reduces the relativity. We consider each result in turn. After validating
that the effects appear to hold in general, we run some internal scope tests, checking
that the patterns of response between question blocks is consistent for the majority of
respondents.
4.1.1 Context and morbidity
By holding time constant, and comparing road accident and cancer risks where the
fatality would occur at the same time—after 2 years in Q4 and 10 years in Q5, the
context questions provide information on how respondents view contemporaneous risks
of cancer and road accident fatalities. Notice that the latency period for cancer is t-1 years,
allowing the 1 year morbidity period to occur and the time of fatality to be equal in the
cancer and road accident cases. This avoids the confound between length of life and
quality of life that is sometimes encounteredwhenmorbidity is presented as an Badd-on^.
A strong preference is indicated for avoiding cancer risk increases as opposed to
road accident risk increases in both questions 4 (C2:R2) and 5 (C10:R10). Twelve
months of illness or morbidity is included in the cancer.
Table 3 Sample demographics
Characteristic Sample (n = 157)
Female (%) 52.6
Age (years)
Mean 39
(s.e.) (5.75)
Median 37.5
Household size
Mean 3.27
(s.e.) (1.36)
Number of children in household
Mean 1.38
(s.e.) (1.19)
Households with children under 6 years old (%) 23.2
Household income (GBP/month)
Mean 2685.52
(s.e.) (2074.88)
Median 2500
Rented home (%) 39.7
Further education (%) 48.0
Experience of cancer (self or close friend or family member) (%) 73.5
Experience of road accidents (self or close friend or family member) (%) 50.3
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The relativities from Q4 and Q5 (C2:R2 and C10:R10) are not significantly different
to one another. This suggests that for cancer risk increases (with 1 year of illness
preceding death) compared to contemporaneous road accident risk increases, the
relativity is not affected by when the risk increases would occur. This implies that risks
of both causes of death are discounted by the individual at the same rate, and that
discounting applies to morbidity and death combined in the cancer case.
Turning to morbidity, the responses to Q8 and Q9 show less illness is preferred to
more and as the amount of illness increases, the relativity increases at a decreasing rate.
The premia for both questions are significantly different than 1.
To test whether morbidity is the only driver of the context effect, a final roads:cancer
comparison question (Q10, C10[2w]:R10[2w]) is included, in which the scenarios both
include two weeks of illness prior to fatality ten years from now. In every case, using
every measure of central tendency and at every level of trimming, the ratio is insignif-
icantly different to one, suggesting that the label of cancer by itself does not give rise to
a cancer premium.18
Overall, the context and morbidity results support the assumptions that context
influences the VSL and that in the cancer to roads comparison the cancer context
18 This suggests that the insights about latency and morbidity might generalise to other latent fatalities
preceded by morbidity, although empirical work will be required to verify this.
Table 4 Central tendency measures of relative size of VSLs compared in each question
Question Untrimmed data Trimmed data
n Geometric mean
[95% confidence interval]
n Geometric mean
[95% confidence interval]
1 (C10R1) 138 1.230
[0.597, 3.631]
133 1.116
[0.576, 2.161]
2 (C10R2) 136 0.556
[0.236, 1.314]
128 0.814
[0.403, 1.643]
3 (C25R2) 136 0.228
[0.095, 0.545]
127 0.280
[0.139, 0.566]
4 (C2R2) 132 11.269
[5.048, 25.156]
125 9.340
[4.806, 18.151]
5 (C10R10) 135 9.697
[4.200, 22.388]
128 9.818
[4.905, 19.652]
6 (C2C10) 135 52.176
[25.783, 105.587]
124 22.297
[12.806, 38.822]
7 (C2C25) 131 79.016
[37.630, 165.920]
117 26.356
[15.097, 46.009]
8 (C10[12]C10[6]) 139 9.118
[4.420, 18.808]
133 8.215
[4.534, 14.89]
9 (C10[36]C10[6]) 130 27.752
[12.946, 59.490]
124 17.051
[8.552, 33.994]
10 (C10[2w]R10[2w]) 139 0.943
[0.614, 1.447]
139 0.943
[0.614, 1.447]
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(including a morbidity period) increases the VSL relative to the roads VSL. This
supports the numerator of the relationship proposed in Eq. (1).
4.1.2 Latency
The latency questions compared death from cancer during the year after next with death
from cancer 10 or 25 years into the future. The person would be exposed today, have a
latency period of 1, 9 or 24 years with no noticeable change to their health, then
12 months’ morbidity, and then they would die.
The central tendencies show a strong preference to avoid cancer the year after next
compared to cancer 10 or 25 years from now (Q6 and Q7), with the relativities for both
of these questions significantly exceeding 1. This lends support to the denominator of
the relationship proposed in Eq. (1), by demonstrating that respondents are on average
willing to accept a larger fatality risk later to avoid a risk increase now, so that latency
reduces the relative size of the implied VSLCANCER.
4.2 Cancer premium
The insights about latency, morbidity and context discussed so far were generated by
questions isolating the dimension of interest, providing easily interpreted findings.
However, surveys will more typically compare scenarios that vary these dimensions
simultaneously, and this was replicated in our survey questions 1–3 which compare
risks of road accident fatalities one or two years from now to risks of cancer fatalities
after 10 or 25 years with one year of morbidity. If the offsetting effects proposed in the
relationship in Eq. (1) are correct, then the elicited relativities from Q1–3 would be
expected to be closer to 1 than either the latency or context question relativities. This is
indeed what we find in our data.
The cancer to roads relativity is insignificantly different to one for both Q1 (cancer
fatality in 10 years versus a roads fatality in 1 year i.e. C10R1) and Q2 (C10R2)
and is significantly lower than one for question three (C25R2). Respondents
appeared to view the difference between Bduring the coming year^ and Bduring
the year after next^ as insignificant because the relativities for C10R1 and C10R2
are statistically indistinguishable. Q3’s (C25:R2) relativity is significantly smaller
than the relativity for Q2 (C10:R2). This suggests that the difference between risks
of death from cancer 10 years from now and risks of death from cancer 25 years
from now is perceived to be significant, when compared to risks of death in a road
accident the year after next. The 24 year latency period is perceived as signifi-
cantly preferable to the 9 year latency. This is further evidence that latency appears
to reduce the VSL for cancer.
4.3 Internal scope tests
The above sections validated the prior assumptions about the direction of preference for
each block of questions, finding that on an aggregate level the sample responses
conform to theoretical expectations. Now, on an individual level, we can identify the
extent to which each respondent’s responses conform to the theoretically predicted
patterns, to investigate their internal consistency (Table 5).
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4.3.1 Q4–5: Context
For 24% of respondents, one or both responses are missing. In questions 4 and 5, the
respondent is consistent if they have the same initial preference between cancer and
road accident risk increases between the questions. Only 3% of individuals have
inconsistent responses. Also, cancer might be considered worse than car because of
morbidity and dread effects. Just 14% of respondents prefer a road accident increase
when time of death is held constant. However, arguably this should not be interpreted
as a test of response quality, but instead as a result in its own right.
4.3.2 Q6–7 Latency
We expect respondents to prefer to avoid the earlier risk increase in both Q6 and Q7. Of
the 70% of respondents who do not have missing responses, just three respondents
(3%) violate this prediction, and only 1 flips between preferring earlier and later. As a
scope test, we expect the respondents to more strongly prefer to avoid the earlier risk
increase in Q7 than in Q6, because of the additional 15 years’ latency. Of course, if
different future life years are valued differently (for example because of the demands of
childcare or perceptions of wellbeing in different stages of life) this may not be true, but
we would expect a majority of respondents to conform. In fact, just 11% of respondents
have a smaller relativity in Q6 than in Q7, but 58% show no difference between the
questions, which could indicate a lack of sensitivity to scope for a majority of this
sample. A plausible alternative explanation is that the difference between 10 and
25 years may not have been very important to respondents, compared to the difference
between Bthis year^ and Blater .^ As such, and if respondents tended to give round
number estimates, this might drive some of the lack of sensitivity.
4.3.3 Q2–3 Context and latency combined
We impose no predictions about whether the relativities in Q2–3 are greater or less than
1, because of the offset between context and latency effects. However, due to the
difference in latency periods we would expect a greater relativity in Q3 than in Q2. This
Table 5 Results of internal consistency and scope tests: Proportions of individuals violating quality checks of
the data
Q2–3 Q4–5 Q6–7 Q8–9
Missing 37/159 = 23% 38/159 = 24% 47/159 = 30% 38/159 = 24%
Inconsistent a No prediction 4/121 = 3% 1/112 = 1% 9/121 = 7%
Absolute difference from 1 is contrary
to prediction b
No prediction 16/115 = 14% 3/111 = 3% 10/112 = 9%
Direction of change in relativity between
questions is contrary to prediction a
12/122 = 10% No Prediction 12/112 = 11% 17/121 = 14%
Same response in both questions a 42/122 = 34% 67/121 = 55% 65/112 = 58% 48/121 = 40%
a =percentage of non-missing responses, b = percentage of non-missing and consistent responses
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holds for the majority of respondents, though 34% are insensitive to the change in
latency period in Q2–Q3, suggesting that the effect of timing is different when the types
of fatality differ. 10% express a smaller relativity in Q3. One or both responses are
missing for 23% of the sample.
4.3.4 Q8–9 Morbidity
We expect respondents to prefer shorter to longer morbidity. We do not encounter any
confound between length and quality of life because in our design length of life is held
constant at 10 years. The difference is entirely the length of morbidity (and correspond-
ing reduction in healthy years of life). A preference for longer morbidity could reflect
that it gives the person longer to prepare for their death, but in general we expect a
higher relativity in Q9 than in Q8, with both relativities greater than 1. Our results
support this to a large extent: just 9% prefer longer morbidity to smaller in both
questions (7% are inconsistent), and just 14% have a smaller relativity in Q9.
However, 40% are insensitive to the difference between the questions.
4.4 Regression analysis
The central tendencies lend support to the CTRt relationship proposed in Eq. (1). There
seems to be a strong effect of both context and latency when they are isolated in survey
questions. However, analysis of the central tendencies alone ignores any influence of
demographics, and can by definition only incorporate comparisons across sample
averages. To address both of these issues we pool the data from all questions in the
survey and run overall regressions for the full sample. The dependent variable is the
natural log of the relativity (regardless of the question that elicited it) and the effects of
context, latency, morbidity and labelling are included as explanatory variables. We
estimate a series of OLS regressions of the pooled logged relativities against question
characteristics and demographics. We cluster on the individual to account for the
elicitation of multiple relativities per respondent. We also present fixed effects regres-
sion results, which control for individual heterogeneity. The results are included in
Table 6, which gives each coefficient with its standard error in brackets.
Model (1) is an OLS regression including context, time until death and morbidity
differences between the questions that underpin the dependent variable (the log of the
relativity) and observable demographic characteristics. The ‘time until death’ variable
is included instead of latency, because it facilitates the comparison between the cross-
cause fatalities (Cancer:Roads) and the within-cause fatalities (Cancer:Cancer), as it
avoids the confound by which the same latency difference could give different life
expectancies depending on the length of the morbidity period. Time until death and
morbidity are the key drivers of the relativity, and although the cancer context dummy
has a positive coefficient, it is insignificant. This suggests that morbidity drives the
context effect for cancer, a result supported by the lack of labelling premium that was
found in question 10 (C10[2w]R10[2w]). Model (2) uses the insight from the central
tendencies that the longer latency and morbidity periods do not appear to be linearly
reflected in their relative severities. That is, there might be a non-linear relationship
between morbidity, time until death and the overall relativities. We explore this by
including squared terms on each of these variables, and these effects are significant in
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the expected directions: additional differences between the times until death will
decrease the relativities at a decreasing rate, while additional morbidity differences will
increase the relativity at a decreasing rate. The overall fit of this model is high,
suggesting that diminishing effects of morbidity and latency are important in explaining
the VSL for cancer.
Demographic variables are largely insignificant, although female respondents are
slightly more willing to take risks of the numerator causes (cancer in the cross-context
questions, or later fatality in the within-cancer latency questions) than men, while those
with experience of cancer (having had it themselves or known a close friend or family
member to have cancer) are significantly less willing to take these risks. However, the
observable differences between individuals do not have much significance in general,
Table 6 Regression analysis of logged relativities (pooled) against question characteristics and demographics
OLS Model 1 OLS Model 2 Fixed Effects
Model 3
Fixed Effects
Model 4
n = 1137 n = 1099 n = 1278 n = 1278
Logged relativity R2 = 0.2469 R2 = 0.2909 R2 = 0.2079
ρ = 0.244
R2 = 0.2456
ρ = 0.245
Cancer context dummy (1 = cancer:roads
comparison)
0.327
(0.295)
−0.722
(0.300)
0.569*
(0.325)
−0.382
(0.341)
Time until death (differential in years) −0.163***
(0.015)
−0.460***
(0.048)
−0.154***
(0.014)
−0.425***
(0.044)
Time until death squared (squared differential) - 0.013***
(0.002)
- 0.012***
(0.001)
Morbidity (differential in months) 0.127***
(0.014)
0.354***
(0.043)
0.122***
(0.014)
0.329***
(0.040)
Morbidity squared (squared differential) - −0.009***
(0.001)
- −0.008***
(0.001)
Experience of cancer 1.027***
(0.375)
1.030***
(0.374)
- -
Age 0.000
(0.023)
−0.002
(0.024)
- -
Female −0.616*
(0.337)
−0.622*
(0.336)
- -
No. children in the household −0.036
(0.126)
−0.041
(0.125)
- -
Further education 0.499
(0.311)
0.487
(0.311)
- -
Road accident experience −0.306
(0.312)
−0.291
(0.311)
- -
Rent −0.142
(0.348)
−0.151
(0.347)
- -
Health state −0.371
(0.232)
−0.383
(0.231)
- -
Constant −0.428
(0.985)
0.052
(0.992)
−0.252
(0.251)
0.086
(0.270)
Asterisks denote p-statistic thresholds with * = p < 0.1, ** = p < 0.05 and *** = p < 0.01.
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and yet individuals in the survey sessions appeared to approach the questions quite
differently.
The potential for unobserved heterogeneity between the individuals in the study
prompts the use of fixed effects analysis. Models 3 and 4 provide fixed effects analysis
with robust standard errors. Individual-specific differences account for about 24% of
the variance in the data. In model (3), which replicates the OLS regression without the
squared terms, the context dummy is significant at the 10% confidence level, and the
coefficient is larger than in the pooled OLS analysis. However, the coefficients on the
latency and morbidity differences retain their sign and significance, and their magni-
tudes are largely unaltered. Model (4) gives the fixed effects including the squared
terms for time until death and morbidity differentials, finding these to be again opposite
in sign to the main effect and significant at the 1% level of confidence. This again
supports the finding of diminishing influence of time and of morbidity on the logged
relativity.
Overall, the regression analysis corroborates the evidence from the central tenden-
cies in supporting the proposed relationship between the VSL for cancer and the VSL
for road accident fatality risks. While the context effect itself is not statistically
significant at the 5% level of confidence, the morbidity effect is significant, suggesting
that morbidity drives much of the preference for the avoidance of cancer risks. We have
shown that longer periods of latency reduce the VSL, ceteris paribus. Both of these
effects are tempered through their diminishing marginal effects on the VSL.
Through central tendency and regression analysis we have contributed a range of new
insights concerning the cancer premium, and provided evidence in support of some
existing intuitions. Isolating latency, morbidity and context has allowed us to verify that
latency and context effects offset one another in the comparison of road and cancer
fatality risks. This provides support to our conjecture that the lack of agreement in the
literature about the presence or absence of a cancer premium might relate to differences
in the latency and morbidity specifications of the cancers used. We can, in addition,
quantify the effects. The regressions show that, in our study, an additional year until
death will reduce the relativity by between 14 and 15% (because the exponents of the
coefficients are 0.850 and 0.857. An additional month of morbidity increases the
relativity by between 13 and 14%. However, when we control for the diminishing
effects of these variables by using squared terms, the absolute magnitude of the
coefficients increase, offset by the opposite signed coefficients on the squared terms.
To summarise, we have shown that additional morbidity periods prior to fatality
increase the relativity at a decreasing rate, and that latency offsets this morbidity effect
by reducing the relativity again at a decreasing rate. As such, relativities for cancers
with long morbidity periods and low latency periods are likely to be high, while
relativities for cancers with short morbidity and long latency are likely to be low.
4.5 Reconstructing the VSL from latency and morbidity parameters
The information gleaned from the regression analyses can be recombined to provide a
menu of relativities between cancer and road accident fatalities, given the latency and
morbidity characteristics of the cancer fatality. For example, for a cancer fatality with
15 months’morbidity and 8 years’ latency, the regression output from model (4) would
suggest a relativity of 1.23. For a sooner cancer (latency 5 years) with longer morbidity
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(24 months) the predicted relativity would rise to 3.21. Conversely, a cancer with
22 years’ latency and just 9 months’ morbidity would generate a predicted relativity of
just 0.23.
To capture these intuitions, we represent the relationships estimated in the Fixed
Effects model (4) as a matrix in Table 7. In this representation, the numbers in the cells
represent the relativity of cancer with given time until death and given morbidity
periods, relative to an immediate, instantaneous road accident. The inputs to the
calculation of this value are the time until death and morbidity difference from the
instantaneous road accident fatality, measured in years and in months, respectively. The
difference between the rows and the columns in the matrices are not uniform, reflecting
the non-linear relationship between the relativity and the latency and morbidity periods.
Nonetheless, the highest relativities correspond to the area with low latency and
relatively high morbidity, and the lowest relativities are found where latency is long
and morbidity periods are short.
To illustrate these intuitions further, we represent the relationships estimated in the
Fixed Effects model (4) as a surface in Fig. 2. In this three-dimensional representation,
the vertical axis represents the natural log of the relativity of cancer with given latency
and morbidity periods, relative to an immediate, instantaneous road accident.
The axes along the horizontal plane represent the difference in the time until death,
and morbidity difference from the instantaneous road accident fatality, measured in
years and in months, respectively. The points highlighted on the surface represent the
three cases outlined above. To find the relativity, one would simply take the exponent
of the logged relativity elicited from reading the graph.
As discussed for the matrix, the slope of the graph is not uniform, which reflects the
difference between the rate at which the latency and morbidity periods influence the
relativity, and the rate at which these effects diminish.
5 Discussion and Conclusions
This paper investigated the relationship between the value of preventing a statistical
cancer fatality and the value of preventing a statistical instantaneous road accident
fatality. We proposed that the context of cancer would increase the relativity and the
Table 7 Matrix of reconstructed relativities comparing risks of cancer with specified morbidity and time until
death, relative to instantaneous road accident fatality risks
Morbidity (y)
Relativity 0 6 12 18 24
Time until death (y) 0 0.744 . . . .
5 0.12 0.647 0.196 3.35 3.212
10 0.035 0.19 0.577 0.984 0.944
15 0.019 0.102 0.309 0.527 0.505
20 0.018 0.099 0.301 0.514 0.493
25 0.033 0.176 0.535 0.938 0.875
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latency associated with cancer would decrease it. This was verified using a Risk-Risk
trade-off study designed to isolate the impact of context, morbidity and latency in
determining the overall cancer premium. The central tendencies indicated a good
degree of consistency over the attributes of the fatality scenarios that we investigated.
Regression analysis supported the proposed relationship, suggesting that morbidity
increases the VSL, and latency decreases it, with morbidity driving the context
premium in these data. This analysis allowed us to estimate the size of the morbidity
and time until death effects for our sample. Both effects are non-linear, with
diminishing marginal effects on the VSL. It also allowed the introduction of demo-
graphic heterogeneity in the affected populations of different cancers, and fixed effects
were used to control for unobserved individual differences.
The usefulness of these results was demonstrated in a policy-relevant application,
where information about latency (via the time until death) and morbidity associated
with a particular type of cancer fatality can be used to reconstruct its appropriate VSL
(relative to an instantaneous road accident fatality for which the value is well
established). As such, the applicability of a Bcancer premium^ can be addressed on a
case-by-case basis. Typically, where the latency period is short and the morbidity
period is long, a case can be made for increasing the VSL and allocating more resources
to the prevention of the cancer than when the cancer fatality would be preceded only by
a short illness and would occur many years from now. The practicalities of such an
approach are admittedly not straightforward, and as such we provide a simpler policy
interpretation of our results in Appendix 2, where we provide an approach that
combines just two CTRt relativities and generates estimates of the effective discount
rate r and the context premium (1+ x), as we outlined in Eq. (1). We can then test the
validity of the application of a B×2^ cancer premium for cancer fatalities. Through these
two methods, the framework is now in place for respecting individuals’ preferences
when making policy decisions that influence the risk of fatality from cancers with
different latency and morbidity periods.
In summary, we have proposed, verified and demonstrated a structural relationship
between cancer and road accident risk valuations. We have conducted a rich analysis
which can encompass a broad variety of cancer morbidity and latency periods and so
Fig. 2 Surface representing the influence of time until death and morbidity on the logged relativity between
the VSL for cancer and for an immediate, instantaneous road accident fatality
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provide a fairly comprehensive framework for considering the likely relative value of
cancers with different characteristics. This approach provides a framework within
which to extend future discussion of cancer valuations, which is flexible and capable
of accommodating the introduction of different discounting hypotheses, cancer
characteristics and latency periods and which could help to reconcile the varied
VSL estimates for cancer that characterise the current literature. We also hope that
the application of cancer valuations can be less arbitrary and better tailored to the
specific properties of the cancer scenario under valuation through the insights
generated by this research.
Appendix 1
Survey text extract describing cancer
Symptoms of cancer were derived from the American Cancer Association website and
chosen to be as specific as possible without losing generality by becoming cancer-specific.
BWe are interested in those cancers that are caused by exposure to harmful
substances that you come across on a day-to-day basis, for example at work or
from near to where you live. They are NOT caused by lifestyle choices like
smoking or drinking to excess, or solely by genetics. Please notice that this
distinction means that your personal risk level is unlikely to differ much from
the average risk.
BAnother important point is that we are talking about cancers where the chance of
survival is extremely small and we shall treat them as terminal. Please be aware
that although cures for some types of cancer might be developed over time, it is
extremely unlikely that a cure would be found for all of the cancers we are
thinking about.
BAlso, there are a wide variety of cancers and they all have different character-
istics. We can’t ask about every cancer separately, so instead we’ll try to cover as
many as we can using groups of cancers with similar characteristics.
BFor the cancers we are concerned with, the symptoms might include unex-
plained weight loss, having fevers and feeling generally unwell, and also having
less energy than before. You will have some pain and might need to be treated
using drugs that make you sick.
BYou would go through stages of illness, each one a bit more severe than the one
before it. It is hard to be precise about how bad the symptoms would be, but
usually they get worse as time passes. A longer time with symptoms means you
would be in each stage of the illness for a bit longer.
BThese are the symptoms of a typical cancer case, and you should imagine that
this is what it would be like for you.^
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Appendix 2
A simple policy application
The analysis in the main text used all questions and all information to generate a
detailed account of the effects of latency and morbidity on the VSL for cancer. This
clearly offers a new and rich set of information for allocative policy decisions.
However, in reality it is not practically feasible for policymakers to use a different
valuation for each cancer case. Given this limitation, we estimate some key underlying
parameters for policy use that will simplify the approach to understanding the
VSLCANCER. This also allows us to test the validity of the application of a multiplier
of 2, which doubles the VSL for cancer compared to a road accident VSL in UK
government policy. We can use the CTRt relationship proposed in Eq. (1) and verified
through the regression analysis to simplify the information from just two relativities
into a context premium (including a fixed morbidity period of 12 months) and an
effective discount rate capturing the effect of latency. In addition to the benefit of
simplifying the analysis of survey relativities, this procedure allows the inference of the
effective discount rate simultaneously with the context premium, which is more
informative than imposing an externally chosen discount rate.
While the previous analysis suggests that morbidity was important, and that the
effect of latency might be non-linear, we prefer to keep the CTRt relationship simple by
incorporating morbidity into the overall context parameter and by accommodating the
effect of latency through a conventional discounting procedure, as in Eq. (1). This
allows us to elicit two key policy-relevant parameters, which are straightforward to
explain and interpret and practically applicable in a policy setting. It also reduces the
requirement for information in the survey scenarios used to elicit the parameters. It is
possible to adapt the relationship in Eq. (1) to incorporate morbidity duration, but this
can only be used in cases where the duration of illness is known.
From Eq. (1) it follows that:
C10
R2
¼ 1þ xð Þ
1þ rð Þ8 ð7Þ
and
C25
R2
¼ 1þ xð Þ
1þ rð Þ23 ð8Þ
so that from Eqs. (7) and (8):
C10=R2
C25=R2
¼ 1þ rð Þ15 ð9Þ
Based on the trimmed geometric means of the C10 /R2 and C25 /R2 ratios from Q2
and Q3, it then follows from Eq. (9) that:
r ¼ 0:0737 ð10Þ
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and hence, by substituting for r in Eqs. (7) or (8), that:
x ¼ 0:434 ð11Þ
The effective discount rate is therefore 7.37% per year and the context premium
incorporating 12 months morbidity is 1.43, implying that cancer fatality risk increases
are perceived to be 1.43 times as bad as road accident risk increases which occur at the
same time, given this illness period. These estimates are within a reasonable range
given previous literature.
In this study, using the generic descriptions of cancer with 12 month morbidity, we
found a context premium of 1.43 (i.e. the VSL for cancer is 1.43 times as high as the
VSL for road accidents, when the fatalities would occur at the same time) and a
discount rate of 7.37%. In combination, these parameters mean that a latency period
of ten years or more in the cancer case reduces the relative value of the latent cancer
fatality and the current period road accident fatality to 1:1. Therefore, we find no
evidence to support the application of a B×2^ cancer premium based on the preferences
of this particular sample of the general public.
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